Patents by Inventor Chan-Kyung Jane Cho

Chan-Kyung Jane Cho has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biomarkers for the detection and screening of down syndrome
    Patent number: 8574860
    Abstract: The disclosure includes assays and methods for screening for risk of Down syndrome and/or trisomy 21 in a fetus. The assays and methods comprise determining the level of at least one biomarker selected from mucin 13 (MUC13), bile salt-activated lipase (CEL), dipeptidyl peptidase 4 (DPP4), carboxypeptidase A1 (CPA1), amyloid precursor protein (APP) and tenascin-C (TNC-C) polypeptides in a test biological sample from a pregnant subject, wherein a decreased level of MUC13, CEL, DPP4, and/or CPA1 polypeptide and/or an increased level of APP and/or TNC-C polypeptide in the test biological sample compared to a corresponding reference biomarker polypeptide level indicates an increased risk of Down syndrome or trisomy 21 in the fetus. The disclosure also includes assays, compositions, immunoassays, and kits for performing the methods disclosed herein.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: November 5, 2013
    Assignee: University Health Network
    Inventors: Eleftherios P. Diamandis, Chan-Kyung Jane Cho, Eduardo Martinez Morillo
  • BIOMARKERS FOR THE DETECTION AND SCREENING OF DOWN SYNDROME
    Publication number: 20120288873
    Abstract: The disclosure includes assays and methods for screening for risk of Down syndrome and/or trisomy 21 in a fetus. The assays and methods comprise determining the level of at least one biomarker selected from mucin 13 (MUC13), bile salt-activated lipase (CEL), dipeptidyl peptidase 4 (DPP4), carboxypeptidase A1 (CPA1), amyloid precursor protein (APP) and tenascin-C (TNC-C) polypeptides in a test biological sample from a pregnant subject, wherein a decreased level of MUC13, CEL, DPP4, and/or CPA1 polypeptide and/or an increased level of APP and/or TNC-C polypeptide in the test biological sample compared to a corresponding reference biomarker polypeptide level indicates an increased risk of Down syndrome or trisomy 21 in the fetus. The disclosure also includes assays, compositions, immunoassays, and kits for performing the methods disclosed herein.
    Type: Application
    Filed: May 9, 2012
    Publication date: November 15, 2012
    Applicant: UNIVERSITY HEALTH NETWORK
    Inventors: Eleftherios P. Diamandis, Chan-Kyung Jane Cho, Eduardo Martinez Morillo